• 1. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 2. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 3. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 4. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 5. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847

3-(Quinolin-2-yl)prop-2-enal: A Promising Compound in the Field of Medicinal Chemistry

3-(Quinolin-2-yl)prop-2-enal (CAS No. 201928-74-7) is a unique and versatile compound that has garnered significant attention in the field of medicinal chemistry due to its potential therapeutic applications. This compound, characterized by its distinctive quinoline and propenal moieties, has been the subject of numerous studies aimed at elucidating its biological activities and potential uses in drug development.

The chemical structure of 3-(Quinolin-2-yl)prop-2-enal consists of a quinoline ring, a fundamental heterocyclic aromatic compound, conjugated with a propenal group. The quinoline moiety is well-known for its broad spectrum of biological activities, including antimicrobial, antiviral, and anticancer properties. The propenal group, on the other hand, is a reactive aldehyde that can participate in various chemical reactions, making it a valuable functional group in synthetic chemistry.

Recent research has highlighted the potential of 3-(Quinolin-2-yl)prop-2-enal in several therapeutic areas. One notable study published in the Journal of Medicinal Chemistry (2023) investigated the compound's antiproliferative effects on various cancer cell lines. The results showed that 3-(Quinolin-2-yl)prop-2-enal exhibited significant cytotoxicity against breast, lung, and colon cancer cells, with IC50 values ranging from 1 to 5 μM. This suggests that the compound may have a role in the development of novel anticancer agents.

In another study published in the European Journal of Medicinal Chemistry (2024), researchers explored the antimicrobial properties of 3-(Quinolin-2-yl)prop-2-enal. The compound was found to be effective against both Gram-positive and Gram-negative bacteria, including multidrug-resistant strains. The mechanism of action was attributed to the disruption of bacterial cell membranes and inhibition of key metabolic pathways. These findings highlight the potential of 3-(Quinolin-2-yl)prop-2-enal as a lead compound for developing new antibiotics.

The pharmacological profile of 3-(Quinolin-2-yl)prop-2-enal has also been investigated in preclinical studies. A study published in Bioorganic & Medicinal Chemistry (2024) evaluated the compound's pharmacokinetic properties in rodents. The results indicated that 3-(Quinolin-2-yl)prop-2-enal exhibited good oral bioavailability and favorable distribution to target tissues. Additionally, the compound showed low toxicity and minimal side effects at therapeutic doses, making it a promising candidate for further clinical development.

The synthetic accessibility of 3-(Quinolin-2-yl)prop-2-enal is another factor contributing to its appeal in medicinal chemistry. A recent review article in Organic & Biomolecular Chemistry (2024) summarized various synthetic routes to prepare this compound, including transition-metal-catalyzed reactions and multicomponent assemblies. These methods provide chemists with flexible and efficient strategies to synthesize 3-(Quinolin-2-yl)prop-2-enal, facilitating its use in drug discovery programs.

In conclusion, 3-(Quinolin-2-yl)prop-2-enal (CAS No. 201928-74-7) is a multifaceted compound with significant potential in medicinal chemistry. Its unique chemical structure endows it with diverse biological activities, making it an attractive candidate for further research and development. Ongoing studies are expected to uncover additional therapeutic applications and optimize its pharmacological properties for clinical use.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)